ERBB2 and cancer: For validation of the upregulation and predictive strength of these 63 genes, we utilized a cohort of 512 ER+/HER2- patients who had undergone taxane-based systemic therapy in the ROC plotter database developed by Fekete & Győrffy for the validation of predictive markers in cancer (16).